

FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICEApplicants Docket Number:  
USHMR2050US NPApplicants:  
GROSSMAN, ET AL.Serial No.  
09/596,114Filing Date:  
JUNE 16, 2000Title of Invention:  
NOVEL VECTORS FOR IMPROVING CLONING AND EXPRESSION IN LOW COPY PLASMIDS

FAX RECEIVED

JAN 29 2003

GROUP 1600

OFFICIAL

## CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Washington, D.C. 20231, at 203-872-9306, on

Date of Deposit January 28th, 2003

Printed Name of Person Signing Certificate Ahmeda O. Daniels

Signature Ahmeda O. Daniels

Total Number of Pages Sent: SIX(6)

Attorney: F. AARON DUBBERLEY

Group Art Unit: 1636

Examiner: LOEB, B.

TO: Commissioner for Patents  
Box  
Washington, D.C. 20231

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- ☒ Amendment, 37 CFR 1.111  
☒ Charge deposit account, in duplicate  
☒ Extension of Time Petition

- ☐ Issue Fee Transmittal & Advance Order  
☐ Maintenance Fee Transmittal

- ☐ Fee Transmittal  
☐ Petition under 37 CFR  
☒ Other Copy of Notice to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures  
☐ Other

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)